A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT03134638

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03134638. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.

Study identification

NCT ID: NCT03134638
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Syros Pharmaceuticals; Industry
Enrollment: 107 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 12, 2017 (Actual)
Primary completion: May 15, 2020 (Actual)
Completion: Jun 24, 2020 (Actual)
Last update posted: Mar 9, 2021

2017 – 2020

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35233	—
Honor Health Research Institute	Scottsdale	Arizona	85258	—
Palo Alto Medical Foundation Group	San Francisco	California	94118	—
University of Chicago Medical Center	Chicago	Illinois	60637	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Columbia University Medical Center	New York	New York	10032	—
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	—
Willamette Valley Cancer Institute and Research Center	Eugene	Oregon	97401	—
Women and Infants Hospital of Rhode Island	Providence	Rhode Island	02905	—
Tennessee Oncology	Nashville	Tennessee	37203	—
Texas Oncology	Austin	Texas	78705	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
Texas Oncology	Fort Worth	Texas	76104	—
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03134638, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 9, 2021 · Synced Nov 14, 2026